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Diagnosis of pulmonary dysfunction is currently almost entirely based on a vast series of physiological changes, but comprehensive
research is focused on determining biomarkers for early diagnosis of pulmonary dysfunction. Here we discuss the use of biomarkers
of lung injury in cardiothoracic surgery and their ability to detect subtle pulmonary dysfunction in the perioperative period.
Degranulation products of neutrophils are often used as biomarker since they have detrimental effects on the pulmonary tissue
by themselves. However, these substances are not lung specific. Lung epithelium specific proteins offer more specificity and slowly
find their way into clinical studies.
1. Introduction
Cardiothoracic surgery, defined as surgery on the heart
and/or the lungs, has been performed since the 1950s
and coronary artery bypass graft surgery, for instance, has
increased to 415.000 procedures a year in theUS (USHospital
Discharge Survey, 2009). From the beginning these proce-
dures were associated with postoperative pulmonary com-
plications [1]. These complications can partly be attributed
to the unique aspects of cardiothoracic surgery, such as the
sternotomy, cardioplegia, and use of cardiopulmonary bypass
(CPB) with the exclusion of lung circulation. Despite con-
tinuous improvements in materials and surgical techniques,
cardiothoracic surgery still causes lung injury, dysfunction,
and delay of pulmonary recovery [2].
Lung dysfunction is common after cardiothoracic surgery
[2] and varies between hypoxemia in all patients [3] and
acute respiratory distress syndrome (ARDS) in 2% of the
patients [4]. Lung dysfunction by itself may not influence
the postoperative course of a patient; only when lung
dysfunction evolves into a lung complication it becomes
clinically relevant. Common pulmonary complications fol-
lowing cardiothoracic surgery are pleural effusion (38%) [5],
atelectasis (20%) [6], phrenic nerve paralysis (32%) [7], and
pneumonia (5%) [8]. Given the high incidence of pulmonary
complications, it is important tomonitor the onset and course
of postoperative lung dysfunction.
Currently there is no gold standard for quantifying
postoperative lung injury and dysfunction. Reported are
a vast series of physiological changes (alveolar-arterial
oxygen pressure difference, intrapulmonary shunt, degree
of pulmonary edema, pulmonary compliance, and pul-
monary vascular resistance) and measurement of inflamma-
tory markers such as neutrophil elastase, myeloperoxidase,
and interleukins [2]. Lung dysfunction, in the form of
ARDS, is determined by specific diagnostic criteria recently
revised according to the “Berlin criteria” [9]. Acute res-
piratory distress syndrome is characterized by the acute
onset of lung injury within one week of a known clini-
cal insult, bilateral opacities on chest imaging, respiratory
failure not fully explained by cardiac failure or fluid over-



















ratio: ≤100mmHg). Mild ARDS
is comparable to the previous acute lung injury (ALI) def-
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2 Disease Markers
Biomarkers, whether in serum, urine, or exhaled breath,
have found limited use for identifying and quantifying
postoperative lung injury. In this review, we focus on the field
of cardiothoracic surgery, where serum biomarkers of lung
injury are being used as a surrogate marker for (sub)clinical
lung injury.
2. Postoperative Pulmonary Dysfunction
A distinction between pulmonary dysfunction and pul-
monary complications following cardiothoracic surgery
should be made [11], where pulmonary dysfunction refers
to alterations in pulmonary function, such as shallow respi-
ration and hypoxemia, and where pulmonary complications
also require associated clinical findings such as atelectasis and
chest radiographic infiltrates.
3. Biomarkers
Biomarkers aremeasurable parameters that reflect the state of
a biological process. An often-cited definition of a biomarker
is as follows: “a characteristic that is objectively measured
and evaluated as an indicator of normal biological processes,
pathogenic processes, or pharmacologic responses to a ther-
apeutic intervention [12].” Biomarkers are used to screen for,
diagnose, or monitor disease and are also used to assess a
therapeutic response [13]. The term biomarker is typically
used for molecular biomarkers measured in blood, which is
also the application we are focusing on in this review.
In cardiothoracic surgery research, biomarkers can serve
as a surrogate endpoint for evaluating new procedures and/or
medical equipment, giving more insight into a cellular level.
Ideally biomarkers have features such as high sensitivity,
high specificity, known reference values, and good predictive
values. In case of a surrogate endpoint, biomarker values
should have a good correlationwith a clinical endpoint. How-
ever, when taking serial measurements during cardiothoracic
surgery each patient serves as his or her own control making
features such as high sensitivity and specificity less important.
Since sample sizes are usually limited in cardiothoracic
surgery research, a biomarker could reveal a difference
between study groups, whereas differences would not appear
when clinical endpoints are considered. Another benefit of
biomarkers is that they could give insight into the mech-
anism of disease, since the measurement is closer to the
exposure/intervention of interest and it may be easier to
relate causally than more distant clinical events. Being more
sensitive, biomarkers could indicate subclinical benefits in a
pilot study, supporting larger clinical studies afterwards.
4. Classification
The pathophysiology of postoperative lung injury is charac-
terized by injury to the alveolar-capillary membrane, inflam-
mation, increased permeability, and pulmonary edema [14].
Accordingly, biomarkers of lung injury can be classified as
such. However, in this review we have focused on biomarkers
originating from the alveolar compartment which can be
measured in the circulation.We have organized the biomark-
ers using their cell of origin.
5. Polymorphonuclear Neutrophils
Polymorphonuclear neutrophils (PMNs) play an important
role in lung injury following cardiothoracic surgery, as their
release products can be detrimental to lung tissue. Moreover,
the lungs harbour a number of leukocytes equal to or even
more than the number of leukocytes present in the systemic
circulation [15]. This is usually referred to as the marginated
pool, which acts as a natural reservoir of leukocytes and is in
dynamic equilibrium with the systemic circulation.
5.1. Neutrophil Elastase. Upon an inflammatory response
PMNs degranulate and release an abundance of cytotoxic
substances, such as serine proteases, metalloproteases, per-
oxidases, and reactive oxygen species (Figure 1) [16]. One
of the serine proteases is neutrophil elastase (NE). Besides
being a biomarker, NE is an enzyme that has an active
role in the development of lung injury. It can degrade
components of the endothelial basement membrane, such
as elastin and collagen [17]. This has been shown by a loss
in integrity of the endothelial vascular barrier, resulting in
increased permeability of the alveolar-capillary membrane
[18]. Neutrophil elastase is thought to hydrolyse junction
proteins such as cadherins, whichmaintain cell-cell adhesion
and diminish barrier function. Similarly, it has been shown
that NE can disrupt the epithelial barrier [19]. Taken together,
NE can be responsible for protein leakage from the blood
stream to the alveolus and vice versa.
Initially, NE was mostly used as a biomarker for the acti-
vation of PMNs in vivo after cardiopulmonary bypass [20],
since extracorporeal circulation activates the complement
system which in turn activates the PMNs [21].
A positive correlation has been observed between NE
plasma concentrations after CPB and postoperative respi-
ratory function, by changes in the respiratory index and
increases in the intrapulmonary shunt [22]. In another study
a positive correlation was found between the NE plasma
concentration and the alveolar-arterial oxygen gradient and
pulmonary vascular resistance [23].
In addition NE has been used to study the effects of
leukocyte depletion during cardiopulmonary bypass [24, 25],
NE inhibitors [26], pump types [27], and biocompatibility of
leukocyte and fat removal filters [28].
Although NE can be a valuable biomarker in assessing
PMNs induced lung injury, it is still only a measure of PMNs
activation and not a specific lung biomarker.
5.2. Myeloperoxidase. Myeloperoxidase (MPO) is a peroxi-
dase enzyme stored in the azurophilic granules of PMNs. Its
primary function is to kill microorganisms in PMNs by form-
ing halide derived oxidants in the phagosome [29]. Ischemia
during cardiopulmonary bypass results in endothelial acti-
vation upon reperfusion [30]. The activated endothelium
and the expression of specific surface adhesion molecules


























Figure 1: Schematic representation of an alveolus with its various cell types and their secretion products which may serve as lung injury
biomarkers.
will be released. MPO measured in blood is a marker for
degranulation of PMNs in plasma and for the infiltration of
PMNs in tissue [32]. Besides being amarker for PMNdegran-
ulation, MPO is often implicated in lung injury. Pulmonary
tissue is often the target of activated PMNs when it is being
reperfused; therefore MPO concentrations are thought to be
a marker of pulmonary injury.
During CPB, pulmonary endothelial permeability cor-
related with postoperative serum concentrations of MPO,
implicating neutrophils having a central role in the develop-
ment of lung injury [33]. However, we and others have shown
that MPO shows a steep increase right after the administra-
tion of heparin [34, 35]. This increase of MPO after heparin
administration is explained by liberation of MPO bound to
the vessel wall [36], which suggests that an increase in plasma
MPOdoes not necessarily represent activation/degranulation
of leukocytes. This would also implicate that MPO is of
limited use as a biomarker for assessing lung injury after CPB,
which requires high dose heparin anticoagulation.
6. Lung Epithelium Specific Proteins
6.1. Soluble Receptor for Advanced Glycation End Products
(sRAGE). The receptor for advanced glycation end products
(RAGE) was originally characterized for its ability to bind
glycation end products of a carbohydrate to a protein. Besides
advanced glycation end products, RAGE has the ability
to bind several other ligands, for example, amphoterins,
S100 proteins, Mac-1, phosphatidylserine, and complement
C3a [37]. Expression of RAGE is encountered on multiple
cell types such as smooth muscle cells, macrophages, and
endothelial cells, but it is also highly expressed in the alveolar
type I cells (Figure 1) of the lungs [38].
Soluble forms of RAGE can be formed by proteolytic
cleavage of full length RAGE bymetalloproteinases or by for-
mation of a splice variant and can be measured in the blood
stream [39]. Accordingly, this led to the potential application
of (s)RAGE as a lung injury marker of alveolar type I cells.
The function of circulating sRAGE is being investigated in
various (clinical) studies and is not yet completely elucidated.
However, sRAGE is thought to contribute to the removal
and/or detoxification of proinflammatory products [39].
Indeed it has been shown that sRAGE is an injury
marker of alveolar type I cells [40]. Uchida et al. found in
patients with ALI that plasma concentrations were signifi-
cantly higher than in patients with hydrostatic pulmonary
edema or in healthy controls. Increased sRAGE plasma
concentrations have also been associated with the use of CPB
and mechanical ventilation in patients undergoing elective
coronary artery bypass grafting [41]. More recently, Tuinman
et al. showed that sRAGE plasma concentrations increased
following valvular and/or coronary artery surgery and that
they depicted an association with pulmonary leak index,
indicating increased permeability of the alveolar-capillary
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membrane [42]. In young children, plasma concentrations
of sRAGE were found to be an independent predictor of
ALI after cardiac surgery with CPB [43]. Furthermore, in
children as well as in adults increased plasma concentrations





higher radiographic lung injury score, longer mechanical
ventilation time, and longer intensive care unit length of stay
[43, 44].
Preoperative measurements of sRAGE are also of value.
In a study where patients underwent elective cardiac surgery,
preoperative sRAGE plasma concentrations were associated
with duration of critical illness and length of hospital stay
[45]. Furthermore, sRAGE was found to be an independent
predictor of length of hospital stay.
Calfee et al. showed that sRAGE plasma concentrations
measured four hours after allograft reperfusion were associ-
ated with poor short term outcome of lung transplantation,
as indicated by longer duration of mechanical ventilation and
longer intensive care unit length of stay [46].This finding was
supported by another study where an association was found
between plasma concentrations of sRAGE and primary graft
dysfunction at 6 and 24 hours following lung transplantation
[47]. Furthermore an association between sRAGE plasma
concentrations measured at 6 and 24 hours following trans-
plantation and mechanical ventilation time was found. The
same authors also established an association between sRAGE
plasma levels measured at both 6 and 24 h postoperatively
with long-term risk for bronchiolitis obliterans syndrome
[48].
6.2. Clara Cell Secretory Protein. Clara cells are secretory
epithelial cells lining the pulmonary airways (Figure 1). The
exact role of these cells still remains unclear, although they
are implicated in having a role in protecting and repairing the
bronchial epithelium [49]. Clara cells are mainly located in
the respiratory bronchioles and they have granules containing
various proteins. One of these secretory proteins is Clara
cell 16 kD secretory protein (CC16), which is referred to
in literature by various names such as uteroglobin (UG),
blastokinin, Clara cell secretory protein (CCSP), Clara cell-
specific 10 kD protein (CC10), and secretoglobin 1A member
1 (SCGB1A1).
Clara cell secretory protein is believed to play a role in
reducing inflammation of the airways [50] and protecting the
respiratory tract against oxidative stress [51]. It is present in
increasing density from the trachea to terminal bronchioles.
Although there is evidence of extrapulmonary synthesis of
the CC16 in the prostate, endometrium, and the kidney, these
concentrations are on average twenty times lower than in the
lungs [52]. This is the reason why CC16 is primarily ascribed
to the respiratory tract and why it is considered to be lung
specific.
With stable baseline serum concentrations of 10–
20 ng/mL, an increase in serum is ascribed to injury to the
alveolar-capillary membrane. When the membrane is known
to be intact it could be related to the integrity of the Clara
cell or the production and clearance of CC16.
Serum concentrations of CC16 have been associated with
injury of the alveolar-capillary membrane and are nowadays
often used as a biomarker of injury to the alveolar-capillary
membrane in different models, such as ALI/ARDS [53,
54], cardiogenic pulmonary edema [54], chest trauma [55],
chronic obstructive pulmonary disease [56, 57], primary graft
dysfunction (PGD) [58], and injury due to fire exposure [59].
However, in the setting of cardiothoracic surgery CC16
has not often been used as a lung injury marker. Serum
CC16 concentrations have been associated with bronchiolitis
obliterans syndrome after lung transplantation [60] and
primary graft dysfunction after lung transplantation [58].
In a more recent study, the same authors showed that even
higher preoperative serum CC16 concentrations, measured
in the recipient, were associated with primary graft dys-
function after lung transplantation [61]. Additionally, CC16
has been utilized as a lung injury marker for comparison
of mechanical ventilation strategies during various surgical
procedures [53], for comparison of a mini-extracorporeal
circuit versus a conventional cardiopulmonary bypass [62–
64], and for evaluation of pulsatile flow during CPB on
lung function [65]. More recently, we have shown that CC16
concentrations correlate with pulmonary dysfunction (as
indicated by the alveolar-arterial oxygen gradient) during
cardiothoracic surgery and that it was possible to differentiate
between off-pump and on-pump coronary artery bypass
grafting [34]. In our opinion, given its small size which
facilitates diffusion into the blood, this is a sensitive and very
useful marker for detecting subclinical injury to the alveolar-
capillary membrane.
6.3. Surfactant Proteins. Pulmonary surfactant is the main
fraction of the epithelial lining fluid in the lungs. Its main
function is to lower surface tension between air and the
alveoli and thereby to prevent alveolar atelectasis at the
end of expiration [66]. Pulmonary surfactant consists of
lipids (90%) and proteins (5–10%). Type II alveolar epithelial
cells are mainly responsible for synthesis and secretion of
pulmonary surfactant (Figure 1), and before surfactant is
secreted it is stored in organelles called “lamellar bodies.”
The lipids of surfactant are mainly phospholipids, with phos-
phatidylcholine being the most abundant. Saturated phos-
phatidylcholine largely consists of dipalmitoylphosphatidyl-
choline (DPPC), which accounts for approximately 40% of
total lipids and is the major surface-active component.
The protein fraction of surfactant is of more interest for
this review. This fraction consists of four different surfactant
proteins, SP-A, SP-B, SP-C, and SP-D. Surfactant proteins B
(14 kDa) and C (6 kDa) are hydrophobic and are involved
in phospholipid packaging, organization of surfactant, and
lowering the surface tension at the air-liquid interface [67,
68]. Via its interaction with DPPC, SP-B has been considered
to stabilize the phospholipid monolayer. Similarly, SP-C is
also thought to be involved in stabilizing the phospholipid
layers that form during film compression at low lung volumes
[69].
The hydrophilic surfactant proteins, SP-A and SP-D, are
predominantly involved in the innate host-defence system
of the lung [70] and belong to the collectin family (along
with mannose-binding lectin). They are assembled as a
trimeric structure with the carbohydrate recognition domain
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connected to a collagenous domain [71]. The carbohydrate
recognition domain has a high affinity for clustered oligosac-
charides commonly found on the surface of viruses, bacteria,
yeast, and fungi, which can lead to agglutination, phagocyto-
sis, and removal bymacrophages and neutrophils or by direct
bacteriostatic and fungistatic effects [72].
So far, the use of surfactant protein leakage in blood
during cardiothoracic surgery is limited. Agostoni et al.
evaluated SP-B as a lung injurymarker after elective coronary
artery bypass grafting with the use of cardiopulmonary
bypass [41]. Immediately after surgery, they found a fourfold
increase of plasma SP-B, which returned to baseline within 48
hours. The authors concluded that SP-B could be a sensitive
and rapid biomarker of lung distress. Unfortunately, due to
small sample size and relatively healthy patients, they could
not relate the change in SP-B to severity of lung injury. The
same group has, however, shown that plasma SP-B levels are
related to alveolar gas diffusion showing a link between SP-B
plasma levels and injury to the alveolar-capillary membrane
[73].
Sims et al. evaluated the use of SP-D as a lung injury
marker in patients undergoing lung transplantation [74].
They found that SP-D serum concentrations were higher in
idiopathic pulmonary fibrosis than in cystic fibrosis, chronic
obstructive pulmonary disease, or pulmonary hypertension.
During transplantation they found that SP-D concentrations
decreased. However, postoperative values were higher in
single lung transplantation as opposed to the bilateral lung
transplantation.The authors suggested that postoperative SP-
D concentrations were more likely to be determined by the
inflamed native lung as opposed to the allograft, leaving the
native lung as the source for SP-D translocation.
Determann et al. have used circulating plasma concen-
trations of SP-A and SP-D to evaluate mechanical ventilation
strategies where a lower tidal volume was used [75]. They
did not find differences in plasma concentrations of these
surfactant proteins, which was consistent with clinical data
as none of the patients showed signs of advanced lung injury.
Shah et al. used plasma SP-D, among other biomarkers, to
better discriminate clinically graded primary graft dysfunc-
tion and to predict 90-day mortality after lung transplanta-
tion [76]. They found that SP-D together with plasminogen
activator inhibitor-1 plasma concentrations, measured 24 h
after transplantation, had an area under the curve of 0.76 for
predicting grade 3 PGD in the first 72 h after transplantation.
Furthermore, SP-D significantly increased prediction over
PGD grading alone in 90-day mortality, although the other
evaluated biomarkers performed even better.
In our experience SP-D can be a valuable marker during
cardiothoracic surgery: we found that SP-D concentrations
correlated with pulmonary (dys) function and that it was
possible to differentiate surgical procedures (off-pump versus
on-pump) [34].
6.4. Krebs von den Lungen 6. Krebs von den Lungen 6
(KL-6) is a mucinous sialylated sugar chain on human
Mucin 1 [77]. Mucin 1 is a transmembrane protein with an
extracellular domain, containing tandem repeat units that
are heavily glycosylated. Mucins line the apical surface of
epithelial cells in the bronchi, bronchioles, and alveoli where
KL-6 is mainly expressed on alveolar type II cells [78] and
expression is upregulated on regenerating alveolar type II
cells [79]. KL-6 can be found in bronchoalveolar lavage fluid
or in serum, and concentrations are elevated in patients
with interstitial lung diseases, such as pulmonary sarcoidosis
[80, 81]. Additionally, KL-6 seems to be a valuable biomarker
in diagnosing bronchiolitis obliterans syndrome after lung
transplantation [82, 83].
Although KL-6 plasma concentrations have been used
as a marker of disease activity in a variety of respiratory
illnesses, the use of this marker in cardiothoracic surgery
remains limited.There is one reportwhere it has been used for
comparing between a mini cardiopulmonary bypass system
and a conventional bypass system, but it failed to detect a
difference between the two systems [63].
7. Inflammatory Secretion Products
The inflammatory secretion products discussed here are
produced by a broad range of cell types; however in the
alveoli the macrophage is one of the major sources. Alveolar
macrophages are located at the luminal interface of the
alveoli or in the interstitium and remove (dust) particles
and/or microorganisms. Since the lungs are in contact
with the outer world, they are exposed to a vast array
of pathogens, chemicals, gasses, and particles. Besides a
mucociliary layer for removal of these substances, alveolar
macrophages are important for “cleaning” and defending the
alveolar-capillary membrane. Upon activation, macrophages
remove pathogens and foreign substances by phagocytosis
and simultaneously secrete mediators of inflammation and
complement proteins. Activated macrophages can be divided
by activation state; these are known as M1 (or classically
activated macrophages) and M2 (or alternatively activated
macrophages) [84, 85]. While the M1 macrophages pro-
mote inflammation, extracellular matrix destruction, and
apoptosis, theM2macrophages promote extracellular matrix
construction, cell proliferation, and angiogenesis. These two
types of activation come with their own characteristic secre-
tory profile of (anti)inflammatory cytokines, chemokines,
and proteolytic enzymes. On the one hand, M1 macrophages
will release proinflammatory cytokines, such as IL-1𝛽, IL-6,
andTNF-𝛼 [86, 87]. Additionally, the chemokines IL-8, IL-10,
MIP-1𝛼, andMIP-1𝛽 and thematrixmetalloproteases 1, 2, 7, 8,
and 12 are released [88], which can degrade collagen, elastin,
fibronectin, and other extracellular matrix components. On
the other hand, M2 macrophages will release chemokines
CCL17, CCL18, and CCL22 along with the anti-inflammatory
cytokines Il-10 and TGF-𝛽 [89, 90].
In the setting of cardiothoracic surgery, with its more
acute characteristics, the secretory products of the M1 ma-
crophages are most interesting for assessing lung injury.
During cardiothoracic surgery the lungs experience is-
chemia/reperfusion when cardiopulmonary bypass is used.
Ischemia/reperfusion is known to be a strong stimulus to M1
macrophages [91, 92], uponwhich the aforementioned proin-
flammatory substances are released. These proinflammatory
substances could be valuable predicting biomarkers for lung
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injury and/or lung dysfunction. And indeed, proteomic anal-
ysis showed that isolated alveolar macrophages, harvested
during the course of ALI/ARDS, had an upregulated inflam-
matory profile [93]. Amongst these upregulated proteins
was cathepsin B, a lysosomal cysteine proteinase, which the
authors suggested to be a biomarker for early diagnoses
of ALI/ARDS. During cardiothoracic surgery, however, this
protein has not yet been used as a biomarker for lung injury.
Monocyte chemotactic protein 1 (CCL2), primarily
secreted by monocytes, macrophages, and dendritic cells,
was associated with complicated inflammatory lung or renal
injury in patients undergoing primary elective coronary
artery bypass grafting [94]. During lung transplantation,
MCP-1 and interferon gamma-induced protein 10 (IP-10)
were associated with the development of primary graft
dysfunction, and from6 to 72 hours following transplantation
MCP-1 and IP-10 concentrations were significantly higher in
patients with primary graft dysfunction [95]. In another lung
transplantation study it was shown that interleukins 6, 8, and
10 were also associated with primary graft dysfunction [96],
where IL-10 peaked at the start of reperfusion and IL-6 and
IL-8 peaked 4 hours after transplantation.
In patients withmoderate chronic obstructive pulmonary
disease undergoing aortic valve surgery, leukocyte filtration
during CPB resulted in lower plasma concentrations of IL-
6, IL-8, and TNF-𝛼 from CPB discontinuation till 72 h
postoperatively [97]. Furthermore, the authors found a linear
correlation between IL-6 and TNF-𝛼 with the alveolar-
arterial oxygen gradient (Aa-O
2
gradient) and an inverse







Besides the advantages described earlier, there are some
limitations to the use of biomarkers. One limitation is
the high variability in measuring biomarkers, which makes
comparing studies more difficult. Most of the variability can
be attributed to preanalytical and/or analytical variability
[98], where preanalytical variability refers to stability over
time and biological variability (e.g., age, sex, and ethnicity),
and analytical variability refers to the performance of the
test in the laboratory (validity, sensitivity, specificity, and
reproducibility, amongst others). The high analytical vari-
ability is illustrated by a study where factors influencing
the measurement of plasma SP-D by ELISA were examined
[99]. It was found that the ELISA configuration (different
manufactures) and the anticoagulant used could have serious
effects on themeasured SP-D concentration. For instance, the
use of EDTA instead of heparin reduced the measured SP-D
concentration by 50%.
Timing is critical when measuring biomarkers. Most
biomarkers reviewed here show a postoperative increase.
However, this increase can be of short duration, preventing
possible detection when the time points for sampling are
not optimally chosen. For instance, we studied SP-D and
CC16 in patients undergoing either on- or off-pump coronary
artery bypass grafting [34]. The largest difference between
these two groups was at the end of CPB, while one hour
after arrival on the intensive care unit the difference between
these biomarkers was no longer significant. Having to sample
many time points limits the cost effectiveness of biomark-
ers.
Failure to identify factors that can influence the mea-
surement of a biomarker can lead to confounding effects.
These effects can be patient characteristics, such as age, sex,
weight, and use of medication, although groups are usually
balanced for these potential confounding effects. An effect
which, for instance, is often overlooked is the stability of
a biomarker when it is stored for a prolonged period of
time. When the inclusion of a study takes months or even
years and the biomarker degrades when it is stored, large
differences in measured biomarker concentrations between
the first included patient and the last included patient can
occur.
9. Concluding Remarks
In this review, we discussed different biomarkers to identify
lung injury after cardiothoracic surgery, most often with the
use of cardiopulmonary bypass. Though many biomarkers
for lung injury are known, they are not often incorporated
in clinical studies. For the several good biomarkers available
for quantifying lung injury after cardiothoracic surgery, the
clinical applications are significant. They enable early detec-
tion of patients with subtle injury when they are adequately
sensitive and specific. In addition, it would assist in the
development of improved surgical techniques to prevent
injury after cardiothoracic surgery. For this purpose a panel of
biomarkers is most informative, especially when biomarkers
for alveolar types I and II cell injury are incorporated.
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